EPHB2 has been reported to promote migratory and invasive activity in breast (27) and cervical cancers (28), whereas its effects are instead inhibitory in colorectal (29), lung adenocarcinoma (30) and bladder cancers (31). This evidence concerns the gene EPHB2 and urinary bladder carcinoma.